Research
Hormonal
Estrogen replacement therapy (ERT) in postmenopausal women improves muscle mass, strength, and power, and enhances the sensitivity of muscle to anabolic stimuli from exercise.
If you are postmenopausal and struggling to maintain muscle strength, talk to your doctor about Estrogen Replacement Therapy (ERT). It can help your muscles respond better to exercise, leading to greater gains in strength and power than exercise alone.
GoodSupportsHIGH confidence
These studies highlight the importance of estrogen in determining the sensitivity of muscle to anabolic signaling... when estrogen levels were raised to that of premenopausal women using estrogen replacement therapy (ERT), the response to anabolic stimuli was normalized
Why this rating
Supported by multiple clinical trials showing improvements in muscle metrics with ERT.
Source
Effect of Estrogen on Musculoskeletal Performance and Injury Risk
Nkechinyere Chidi-Ogbolu et al. · Frontiers in Physiology · 2019
DOI 10.3389/fphys.2018.01834
narrative_reviewCited 358×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High estrogen levels during the ovulatory phase of the menstrual cycle decrease ligament stiffness by inhibiting lysyl oxidase activity, leading to increased knee laxity and a significantly higher risk of anterior cruciate ligament (ACL) injury.Good
- Oral contraceptives (OCs) that maintain stable, moderate estrogen levels reduce the cyclic fluctuation in knee laxity and are associated with a lower risk of ACL injury compared to women with natural menstrual cycles.Good
- High estrogen levels decrease tendon stiffness by inhibiting lysyl oxidase activity, which may protect muscles from eccentric injury but can negatively impact performance by reducing power output.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →